A Phase 4 Study Using a Test-Negative Design to Evaluate the Effectiveness of a 20-valent Pneumococcal Conjugate Vaccine Against Vaccine-type Radiologically-confirmed Community-acquired Pneumonia in Adults >/= 65 Years of Age
Latest Information Update: 13 Apr 2025
At a glance
- Drugs Pneumococcal 20-valent conjugate vaccine (Primary)
- Indications Community-acquired pneumonia
- Focus Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 17 Apr 2023 Planned End Date changed from 26 Jun 2027 to 4 Jun 2027.
- 17 Apr 2023 Planned primary completion date changed from 26 Jun 2027 to 4 Jun 2027.
- 14 Dec 2022 Planned End Date changed from 4 Jun 2027 to 26 Jun 2027.